From September 25th to 28th, 2025, the HOSPITAL EXPO 2025, a leading event in the medical industry in Southeast Asia, was grandly launched in Jakarta.
As the most professional medical exhibition in Indonesia with a 35-year history, this grand event has attracted exhibitors and professional visitors from over 40 countries around the world and has become a core cooperation platform connecting suppliers, purchasers and manufacturing enterprises in the global medical industry chain.
The POCT platform under Wuhan Shengzhiyuan, consisting of the SZY-H01 handheld detector and the SZY-1100, forms a hierarchical medical treatment solution that meets the demand for rapid screening equipment in this region. Focusing on the field of early screening for chronic diseases, with the portability of the equipment and its multi-scenario adaptability, it has become an important bridge connecting “Made in China” with the medical needs of the grassroots in this region.
As a “palm-sized” detection tool, the SZY-H01 has a body size of only 220mm×100mm×75mm and is so light that it can be held with one hand, perfectly adapting to the narrow operation space of primary medical care points and the rapid response needs at emergency sites. Its core advantages include: extremely fast response (test results are issued within 3 to 15 minutes), zero cold chain burden (stored at room temperature of 2 to 30℃), and user-friendly operation (no calibration design, repeatability coefficient of variation does not exceed 5%), which can meet the requirements of immediate diagnosis in remote areas.
The SZY-1100 dry fluorescence immunoassay analyzer, driven by both “reliable detection performance” and “efficient operation experience”, helps small and medium-sized medical institutions enhance their detection capabilities. Its core advantages include: It features four major characteristics: ultra-fast response (results issued within 10 seconds), strong sample compatibility (supporting whole blood, serum, plasma and urine), zero cold chain burden (stored at room temperature of 2-30℃), and convenient operation. It is widely applicable to various departments of medical institutions, community medical points, physical examination centers and scientific research laboratories. With stable test results, flexible scene adaptation and rapid response capabilities, Provide practical solutions for immediate diagnos
The testing items of Wuhan Shengzhiyuan Company cover 26 indicators in 11 categories including cardiovascular diseases, inflammation, renal function, bone metabolism, etc. Its core advantages are reflected in three aspects: The first is the ability of multi-disease joint screening, supporting the detection of combined items such as myocardial triathlon (cTnI/CK-MB/Myo) and PCT/IL-6, which can simultaneously assess various clinical conditions such as cardiovascular emergencies and infectious diseases, shortening the diagnostic window period. Second, it combines high precision and high efficiency, with a detection sensitivity reaching the ng/mL level and a single detection time of less than 15 minutes, which can quickly provide reliable basis for clinical decision-making. Thirdly, it has a wide range of sample compatibility, supporting various sample types such as whole blood and serum, meeting the testing needs of different clinical scenarios and enhancing the convenience and applicability of testing.
As a national “Little Giant” enterprise specializing in niche markets, Wuhan Shengzhiyuan adheres to the core concept of “technological innovation + global health”, fulfills the mission of “serving a healthy life with biotechnology”, and builds a complete industrial chain from raw material research and development to testing services. Relying on the collaborative advantages of its four major technical platforms – biochemical, chemiluminescence, POCT, and reference laboratory – Provide innovative solutions for the global health cause.
Post time: Sep-30-2025